Objective: Recent studies have shown that Chemokine (C-X-C motif) ligand 14 (CXCL14), a newly secreted by brown adipose tissue, plays an important role in the pathogenesis of metabolic syndrome. However, clinical significance has not been elucidated in human. The aim of this study is to assess correlations between serum CXCL14 levels and clinical parameters among the patients with type 2 diabetes mellitus (T2DM).

Method: A total of 176 subjects with T2DM were recruited. Serum CXCL14 concentration was determined by ELISA. We examined the association of serum CXCL14 levels with the anthropometric parameters and laboratory values, abdominal CT image information, surrogate markers used for evaluating the pathological state of DM, obesity and atherosclerosis.

Result: Serum CXCL14 levels correlated positively with body mass index and waist circumference, subcutaneous and visceral fat area, estimated glomerular filtration rate, serum levels of ALT, UA, TC, LDL-C, TG, FT3, C-peptide (CPR), neuregulin 4, fibroblast growth factor 21, urine levels of CPR, 8-hydroxy-2’-deoxyguanosine. In contrast, those were inversely correlated with age and pulse wave velocity, plasma levels of adiponectin. Multiple linear regression analysis revealed plasma levels of CPR (β=0.227, p=0.038) and fatty liver index (FLI; β=0.205, p=0.049) to be the only parameters showing independent statistically significant association with serum CXCL14 levels.

Conclusion: Serum CXCL14 levels were independently associated with plasma CPR and FLI in patients with T2DM. In this case, high concentration of plasma CPR might reflect insulin resistance rather than β-cell function, because CXCL14 showed simple correlations with obesity-related parameters. Collectively, these data suggested serum CXCL14 levels in type 2 DM might be useful predictors of insulin resistance and abdominal fat accumulation.


Y. Matsushita: None. Y. Hasegawa: None. N. Takebe: None. Y. Ishigaki: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.